Uncategorized

Maximizing GLP-1 Market Exclusivity: Leveraging Patent Term Extension (PTE) and NCE Exclusivity to Protect Blockbuster Status

In the fiercely competitive landscape of biotech innovation, securing and maintaining market exclusivity isn’t just a strategic advantage—it’s a necessity for blockbuster success. The recent surge in GLP-1 receptor agonists, driven by their transformat…

Maximizing GLP-1 Market Exclusivity: Leveraging Patent Term Extension (PTE) and NCE Exclusivity to Protect Blockbuster Status Read Post »

Uncategorized

Post-LOE? Win the War in the “Inactive” Ingredients: Your API Is Generic. Your Excipients Don’t Have to Be

In the fiercely competitive world of pharmaceuticals, the battle for market dominance isn’t just about the active pharmaceutical ingredient (API). It’s about the entire formulation — especially the excipients that make up the inactive ingredients. Yet,…

Post-LOE? Win the War in the “Inactive” Ingredients: Your API Is Generic. Your Excipients Don’t Have to Be Read Post »

Biotechblog
Scroll to Top